Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature (Q38042191)

27 August 2017

title

Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature (English)

1 reference

enzyme replacement therapy

27 August 2017

main subject

0 references

1 reference

Antonio Pisani

1

1 reference

27 August 2017

Bianca Visciano

2

1 reference

27 August 2017

Graciana Diez Roux

3

1 reference

27 August 2017

Massimo Sabbatini

4

1 reference

27 August 2017

Caterina Porto

5

1 reference

27 August 2017

Giancarlo Parenti

6

1 reference

27 August 2017

Massimo Imbriaco

7

1 reference

27 August 2017

language of work or name

1 reference

11 August 2012

1 reference

Molecular Genetics and Metabolism

27 August 2017

published in

1 reference

27 August 2017

volume

107

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

267-275

1 reference

High incidence of later-onset fabry disease revealed by newborn screening

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Narrative review: Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

7 January 2021

Pediatric Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Patients with Fabry disease on dialysis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Onset and progression of the Anderson-Fabry disease related cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Quality of life of patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Agalsidase alfa and kidney dysfunction in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Fabry disease: guidelines for the evaluation and management of multi-organ system involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Clinical trial for Fabry disease faces continuing hurdles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy and Fabry nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Natural history of Fabry disease in females in the Fabry Outcome Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Fabry disease: overall effects of agalsidase alfa treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Kidney transplantation in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Clinical benefit of enzyme replacement therapy in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Clinical features of and recent advances in therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

The heart in Anderson-Fabry disease and other lysosomal storage disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Right ventricular involvement in patients with Fabry's disease and the effect of enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Cardiac manifestations of Anderson-Fabry disease in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Endocrine dysfunction in patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Excellent outcome of renal transplantation in patients with Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Kidney transplant outcomes in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement in Anderson-Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Blood Pressure, Proteinuria and Nephropathy in Fabry Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Predicting initiation and progression of chronic kidney disease: Developing renal risk scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Management of glomerular proteinuria: a commentary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

ACE activity is modulated by the enzyme α-galactosidase A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Relief of pain of Fabry's disease by diphenylhydantoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Fabry disease: recognition and management of cutaneous manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Gene therapy for lysosomal storage diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Targeting glycosylation as a therapeutic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.08.003

10.1016/J.YMGME.2012.08.003

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference